Scientists Discover a Protein Potentially Preventing Brain Changes from Alzheimer’s and Parkinson’s
Researchers have identified a protein that could halt brain changes linked to Alzheimer’s and Parkinson’s diseases. The study, published in Nature Communications, was conducted by scientists at Baylor College of Medicine. It reveals that tubulin, a protein traditionally recognized for constructing internal cell structures, might stop harmful protein clumps from forming in brain cells.
Alzheimer’s disease is associated with tau protein accumulation, while Parkinson’s disease involves alpha-synuclein. Both proteins, when misfolded, aggregate into toxic clusters that damage neurons, leading to issues such as memory loss, cognitive decline, and movement difficulties.
Previous scientific efforts largely concentrated on eliminating these clumps. However, this latest research proposes another approach: encouraging proteins to behave normally rather than blocking them entirely.
Ram Bishnoi, MD, MBA, an associate professor of psychiatry, describes the study as offering “a concrete, testable mechanism” for addressing this issue.
Tubulin, a microtubule component, functions as a molecular switch. It influences whether tau and alpha-synuclein become harmful or remain beneficial. The research indicates tubulin interacts with tau and alpha-synuclein within cellular compartments called condensates, where both healthy and harmful protein versions reside.
“Tubulin is drawn into condensates where both proteins accumulate,” Bishnoi explained. “It competes for binding sites, maintaining their functional shapes.” However, if tubulin levels drop, harmful clumping of the proteins occurs.
Lowering tubulin levels in cell models showed a marked increase in harmful protein buildup and visible neuron loss, exemplifying tubulin’s protective role.
The study suggests the critical factor is not the condensates themselves but the presence of tubulin. “It’s not the condensate itself that’s good or bad, it’s whether tubulin is in the room,” Bishnoi said.
This new understanding might reshape neurodegenerative treatment. Instead of eliminating harmful protein deposits, scientists could redirect proteins to beneficial pathways.
The study implies a balanced approach, focusing on sustaining high tubulin levels to counteract toxic protein formations. Such a shift aligns with clinical observations of early microtubule network decline in Alzheimer’s.
Despite promising laboratory results, further testing in animal models and human studies is necessary. Microtubule-targeting drugs are challenging, as microtubules are integral cellular structures found throughout the body.
“Animal studies are the obvious next step,” Bishnoi said. Nonetheless, the research offers a clearer direction for future studies. “This is a mechanistic insight that strengthens the case for a ‘redirect rather than demolish’ strategy,” Bishnoi concluded, asserting that tubulin should be viewed as a lever, not yet a proven treatment.
Reference: Lucas, L., Tsoi, P.S., Quan, M.D., Choi, K.-J., Ferreon, J.C., and Ferreon, A.C.M. (2026). Tubulin transforms Tau and α-synuclein condensates from pathological to physiological. Nature Communications. [online] doi:https://doi.org/10.1038/s41467-026-69618-3.